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Abstract: The cytolethal distending toxins (CDTs) are a family of exotoxins produced  
by a wide range of Gram-negative bacteria. They are known for causing genotoxic stress  
to the cell, resulting in growth arrest and eventually apoptotic cell death. Nevertheless, 
there is evidence that CDTs can also perturb the innate immune responses, by regulating 
inflammatory cytokine production and molecular mediators of bone remodeling in various 
cell types. These cellular and molecular events may in turn have an effect in enhancing 
local inflammation in diseases where CDT-producing bacteria are involved, such as 
Aggregatibacter actinomycetemcomitans, Haemophilus ducreyi, Campylobacter jejuni  
and Helicobacter hepaticus. One special example is the induction of pathological  
bone destruction in periodontitis. The opportunistic oral pathogen Aggregatibatcer 
actinoycemetemcomitans, which is involved in the aggressive form of the disease, can 
regulate the molecular mechanisms of bone remodeling in a manner that favors bone 
resorption, with the potential involvement of its CDT. The present review provides an 
overview of all known to-date inflammatory or bone remodeling responses of CDTs 
produced by various bacterial species, and discusses their potential contribution to the 
pathogenesis of the associated diseases. 
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1. Introduction 
The family of cytolethal distending toxins (CDTs) consists of a number of bacterial protein 
exotoxins expressed by a broad range of Gram-negative bacteria, with a potential involvement in the 
pathogenesis of a diverse range of human infections. They can be described as genotoxins, as their 
main action is to elicit DNA damage responses on the intoxicated host cells. Consequently, their  
action leads to cell cycle arrest and eventually cell apoptosis [1,2]. The CDT holotoxin consists of 
three subunits, namely CdtA, CdtB and CdtC. The CdtA and CdtC subunits mediate the internalization 
of the CdtB subunit into the cell, which is a molecule functionally homologous to deoxyribonuclease I. 
It is therefore CdtB which is responsible for the induction of these deleterious effects on the host cells. 
Apart from these well-characterized effects of CDTs, the literature indicates that CDTs may also be 
involved on other aspects of the pathogenesis of infection, such as the establishment of a chronic 
inflammatory response [3,4]. It is therefore the aim of this review to identify and present the current 
state of the literature with regards to the role of CDTs on host inflammatory responses, as well as the 
associated effects on bone remodeling. 
2. Host Inflammatory Responses to Cytolethal Distending Toxins 
Inflammation is a process that is triggered in response to a noxious stimulus, such as a bacterial 
pathogen or its virulence factors. Many bacterial virulence factors can act as pathogen-associated 
molecular patterns (PAMPs), which are highly conserved bacterial structures. Pattern recognition 
receptors (PRRs) are transmembrane or intracellular receptors of eukaryotic cells, specialized in the 
recognition of PAMPs. Therefore, PRRs are responsible sensing and responding to the invading 
bacteria. Examples of PRRs are the network of Toll-like (TLRs), nucleotide-binding oligomerization 
domain (NODs) and nod-like receptors (NLRPs) [5]. Activation of PRRs results in the maturation and 
extracellular secretion of cytokines, such as interleukins (ILs), that can thereafter exert their biological 
roles [6]. Cytokines are a group of diverse molecules that mediate the cell-to-cell signaling during the 
initiation and establishment of inflammation. As the CDTs are well established virulence factors with 
potential pro-inflammatory actions upon host cells, they can certainly classify as PAMPs. The effects 
of CDT on inflammation may not be necessarily restricted to a particular member of this toxin family. 
Accordingly, various host cell types are responsive to CDTs, in terms of host inflammatory responses. 
This section summarizes the inflammatory responses of host cells to CDT, according to each  
specific member of this toxin family. The literature search yielded pertinent publications in the  
cases of Aggregatibacter actinomycetemcomitans, Haemophilus ducreyi, Campylobacter jejuni and 
Helicobacter hepaticus. A summary of the associated effects and corresponding literature is provided 
in Table 1.  
  
Cells 2014, 3 238 
 
 
2.1. Effect of Aggregatibacter actinomycetemcomitans CDT 
Aggregatibacter actinomycetemcomitans is a Gram-negative facultative anaerobe, which is highly 
implicated in the pathogenesis of localized aggressive periodontitis, a disease leading to tooth loss in 
adolescents or young adults. This species expresses two protein exotoxins, namely a leukotoxin and a 
CDT, which is a unique property of A. actinomycetemcomitans, among all known oral species [7,8]. 
While the CDT of A. actinomycetemcomitans has been shown to exert its “classical” growth inhibitory 
effects in human T-lymphocytes [9], B-lymphocytes [10], mononuclear cells [11], epithelial  
cells [11,12], gingival fibroblasts and periodontal ligament cells [13,14], there is also evidence that this 
toxin is involved in the stimulation of cytokine production by the host. 
The first indication on such an effect came from the study of Akifusa [11]. This study used 
recombinant A. actinomycetemcomitans CDT holotoxin to challenge isolated human peripheral blood 
mononuclear cells (PBMCs), and identified that it was able to induce the synthesis of IL-1β, IL-6, and 
IL-8, but not tumor necrosis factor (TNF)-α, IL-12, or granulocyte-macrophage colony-stimulating 
factor (GM- CSF). When the different subunits were tested individually in this experimental system, 
CdtC appeared to be a more potent inducer of these cytokines, compared to CdtB, indicating that 
cytokine-inducing action is independent of the deoxyribonuclease I activity of the toxin (which is 
conferred by CdtB). A synergistic cytokine-inducing capacity was also demonstrated, most markedly 
in the case of interferon (IFN)-γ. None of the individual subunits demonstrated IFN-γ-stimulating 
capacity, whereas higher concentrations of the combination of CdtB and CdtC, and particularly all 
three subunits together, demonstrated a strong stimulatory effect. The three primary cytokines shown 
to be induced in PBMCs by A. actinomycetemcomitans CDT are of pro-inflammatory nature. Hence 
their induction is commensurate with the inflammatory traits of periodontal diseases. IL-8 in particular 
is a major chemokine, whose presence is responsible for recruiting neutrophils in the affected area, 
hence intensifying the histopathological events of inflammation [15]. IL-1β and IL-6 are also consider 
osteolytic cytokines, with a primary role in osteoclast formation and subsequent bone resorption [16], 
which is the hallmark of periodontitis. Hence, their induction by may denote an effect on the initiation 
of inflammation in the periodontal tissues that could lead to the pathological process of periodontal 
tissue breakdown, and hence periodontitis. 
The effect of A. actinomycetemcomitans CDT has also been investigated on the production of nitric 
oxide (NO) by murine peritoneal macrophages [17]. NO is a free radical and a crucial inflammatory 
mediator. It was found that CDT caused a rapid inhibition of NO production by these cells, which was 
directed towards IFN-γ-dependent inflammatory pathways, and was independent of anti-inflammatory 
cytokines IL-4 or IL-10. This was interpreted as an immunosuppressive effect of CDT, beyond  
its growth inhibitory and apoptotic capacities, which could be involved in the pathogenesis of  
A. actinomycetemcomitans–associated periodontitis. Hence, inhibition of NO production in macrophages 
by A. actinomycetemcomitans CDT could putatively hinder a cascade of pro-inflammatory events that 
lead to elimination of the invading bacterial pathogens, favoring the establishment of chronic 
periodontal infection. 
Apart from cells of the immune system, structural cells including gingival fibroblasts (GF) and 
periodontal ligament (PDL) cells have been studied for their inflammatory responses to CDT. By the 
use of CDT-deletion mutants, it was found that, although A. actinomycetemcomitans induced IL-6,  
Cells 2014, 3 239 
 
 
IL-1β and TNF-α gene expression in GF, the CDT was actually not in involved in these transcriptional 
events. Nevertheless, rather than transcription, IL-6 cytokine secretion was stimulated by  
A. actinomycetemcomitans challenge, and CDT conferred a partial additive effect to this capacity.  
On the contrary, there was no difference in IL-1β or TNF-α secretion. The gene expression of the 
different receptor subtypes for IL-6, IL-1β and TNF-α cytokines was also not affected by  
A. actinomycetemcomitans, either this expressed CDT or not [18]. Therefore, A. actinomycetemcomitans 
induces IL-6 production in GF, albeit with only partial involvement of the CDT. Accordingly, in 
another study it was shown that soluble surface extracts from A. actinomycetemcomitans cells 
stimulate the production of several pro-inflammatory cytokines (including IL-1β, TNF-α, IL-6, IL-8, 
MIP-1β) by whole human blood, but the CDT or the leukotoxin were not crucial in this respect, as 
demonstrated also by the use of a double mutant for these two toxins [19]. 
Of interest is also a study on inflammasome expression in human mononuclear cells (MNLs),  
in response to A. actinomycetemcomitans [20]. Inflammasomes are intracellular complexes that are 
activated by the PAMP-PRR interaction, responsible for the maturation and release of IL-1 cytokines 
by cells of the immune system [21]. It was shown that A. actinomycetemcomitans does not affect the 
expressions of NLRP1, NLRP2 and Absent In Melanoma (AIM)2 inflammasome sensors, or their 
effector Caspase-1. Nevertheless, it does cause an up-regulation of the NLRP3 and a down-regulation 
of the NLRP6 sensor. This effect was not dependent on the leukotoxin or the CDT, as demonstrated by 
the use of the CDT-deletion strains. Hence, the capacity of A. actinomycetemcomitans to regulate the 
expression of inflammasomes does not appear to be attributed to its CDT [20]. 
The nature on the host cell receptor via which A. actinomycetemcomitans CDT exerts its actions is 
not clear. Yet, there are indications that the glycosphingolipid GM3 can act as one [22,23]. The 
receptor binding capacity of CDT is attributed to the aromatic aminoacids of the CdtA subunit [24,25], 
but not restricted to these [26]. 
Collectively, A. actinomycetemcomitans components other than the CDT appeared to be stronger 
regulators of pro-inflammatory cytokines in the various experimental systems. However, the  
cytokine-inducing capacity of A. actinomycetemcomitans CDT appears to be evident in PBMCs and 
GF, particularly in the case of IL-6, a cytokine with a pronounced role in the stimulation of bone 
resorption [27]. Apart from the regulation of IL-6, the potential effects of CDT on bone resorption are 
further discussed in the next section. 
2.2. Effect of H. ducreyi CDT 
Haemophilus ducreyi is a Gram-negative species that is the etiological factor of chancroid, a disease 
characterized by genital ulcers and regional lymphadenitis. It expresses a CDT which is highly 
homologous to that of A. actinomycetemcomitans, exhibiting 96% amino-acid sequence identity. For 
this reason, it has also been used in its purified form as a model CDT in experimental systems relevant 
to A. actinomycetemcominans and periodontal pathogenesis. In one such example, purified H. ducreyi 
CDT was able to induce the secretion, but not transcription of IL-6 by GF [18]. Accordingly, it has 
also been shown that normal cells, as well as cancer cell lines, intoxicated with H. ducreyi CDT were 
induced to express several cytokines, particularly IL-6, IL-8 and IL-24 [28]. Nevertheless, in another 
in vitro study, purified H. ducreyi CDT partially inhibited the production of TNF-α, IL-6, IL-8, and  
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IL-12 by monocyte-derived dendritic cells, thus hampering the early stage immune responses to  
H. ducreyi [29]. Hence, although there is still limited volume of literature on this theme, H. ducreyi 
CDT may stimulate or inhibit cytokine production, depending on the experimental cell system employed. 
2.3. Effect of Campylobacter jejuni CDT 
Campylobacter jejuni is a Gram-negative species associated with enterocolitis, a local acute 
inflammatory response that involves intestinal tissue damage and diarrhea. The intestinal epithelium is 
a physical barrier that responds to C. jejuni infection by eliciting an inflammatory response. C. jejuni is 
yet another species that expresses a potent CDT, which can modulate the host inflammatory responses 
of the gut epithelium. An early study using intestinal epithelial cells has shown that C. jejuni can 
induce IL-8 release, attributed to a large extent to its CDT. Indeed, anti-CDT antibodies neutralized its 
capacity to stimulate IL-8 release [30]. In other studies involving human intestinal epithelial cells, it 
was confirmed that infection with C. jejuni or just its outer membrane vesicles, was able to stimulate 
the production of pro-inflammatory IL-8, as well as the anti-inflammatory cytokine IL-10. However, 
CDT-deficient strains elicited similar effects, suggesting a CDT-independent mode of action [31,32]. 
When the effect of C. jejuni challenge was considered on human colonic epithelial cells, both IL-8  
and TNF-α cytokines were up-regulated. Its ability to stimulate IL-8 secretion was reduced when 
CDT-deletion strains were used, indicating a crucial role of CDT here, which was also dependent on 
the activation of NF-κB and toll-like receptor (TLR) signaling [33]. It should be reminded that 
transcription factor NF-κB activates a number of pro-inflammatory cytokine genes, including IL-1β, 
IL-6, IL-8 and TNF-α [34]. Therefore, it possesses a key role in the initiation of the inflammatory 
events in response to bacterial challenge. In an interaction model using human monocytic cells,  
C. jejuni was able to induce a number of pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6,  
IL-8, and TNF-α, but CDT was not involved [35,36]. Collectively, there is some evidence that the 
CDT of C. jejuni stimulates IL-8 production by gut epithelial cells, which may promote neutrophil 
migration and inflammatory events in the intestinal tissue. 
2.4. Effect of Helicobacter hepaticus CDT 
Helicobacter hepaticus is a Gram-negative CDT-producing species, associated with chronic 
gastrointestinal inflammation and neoplasia. It is also involved in the development of typhlocolitis  
and chronic hepatitis. The studies available in the literature regarding the inflammatory effects of  
H. hepaticus CDT are primarily using animal infection models, rather than in vitro models. Challenge 
of IL-10(−/−) mice with isogenic H. hepaticus mutants showed that CDT is not required for 
colonization of the murine gut. Despite this, a CDT-deficient mutant significantly diminished the 
capacity of H. hepaticus to induce lesions in this murine model of inflammatory bowel disease [37].  
In line with these findings, both a wild-type H. hepaticus and its derivative CDT-deficient mutant 
successfully colonized the intestinal tissue of IL-10(−/−) mice. Still, only the wild-type infected mice 
developed eventually typhlocolitis. However, at longer periods the CDT-deficient mutant could not be 
detected any further in the mice, but the wild-type strain could persist for longer periods [38].  
In line with this finding, in another study using an isogenic H. hepaticus CDT-deficient mutant to 
infect Swiss Webster mice it was shown that the presence of the toxin was important for longer term 
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colonization of this species, and associated with down-regulation of colonic IL-10 production [39].  
In yet another study, infection with an isogenic H. hepaticus CDT mutant induced chronic hepatitis in 
mice. The pathological traits were comparable to those elicited by the wild-type H. hepaticus, with the 
exception that the latter caused additionally hepatic dysplasic nodules. Moreover, the wild-type 
infected mice demonstrated significantly enhanced hepatic tissue expression of TNF-α, IFN-γ and IL-6 
[40]. Collectively, it appears that H. hepaticus CDT is not required for intestinal colonization, but is 
important for eliciting the chronic inflammatory response associated with colitis, and some of the 
histopathological traits of colitis and hepatitis. 
3. Bone Remodeling Responses to Cytolethal Distending Toxins 
Special mention should be made to the potential of CDT to perturb bone metabolism, particularly 
by interfering in the signaling for osteoclast differentiation. Among all CDT-producing species, it is 
the oral pathogen A. actinomycetemcomitans for which this virulence property could be of relevance. 
That is because periodontitis, in which A. actinomycetemcomitans is involved as a putative pathogen, 
pertains bone destruction of the tooth-supporting tissue. Hence, periodontitis is the only bone-related 
pathology in which a CDT family member may be involved. 
Receptor activator of NF-κB ligand (RANKL) is a membrane-bound or soluble ligand expressed by 
osteoblasts, fibroblasts and activated T-cells and B-cells. By binding onto its cognate RANK receptor 
on the surface of pre-osteoclasts, it triggers their differentiation into mature osteoclasts, which are the 
cells responsible for bone resorption. On the contrary, osteoprotegerin (OPG) is a soluble decoy 
receptor, responsible for binding to RANKL and therefore for blocking its action. This system of 
molecules is crucial for bone resorption, and the relative RANKL/OPG ratio is shown to be elevated in 
bone-destructive periodontal disease [41–44]. 
The current literature related to the RANKL-OPG system and A. actinomycetemcomitans CDT is 
pertinent to in vitro experimental systems. A. actinomycetemcomitans was able to induce RANKL gene 
expression, as well as cell-membrane RANKL protein up-regulation, in GF and PDL cells, which are 
both structural cells of the periodontium. However, OPG gene expression or secretion remained 
unaffected. An A. actinomycetemcomitans CDT-deletion mutant was not able to induce RANKL 
expression, in contrast to its parental wild-type. In agreement with this finding, pretreatment of  
A. actinomycetemcomitans wild-type with antisera raised against CDT, abolished RANKL expression [45]. 
Inhibition of IL-6, IL-1, TNF-α or prostaglandin E2, which are all well accepted mediators of  
RANKL induction, did not inhibit A. actinomycetemcomitans-induced RANKL expression [18].  
This demonstrates that the mechanism of RANKL induction by A. actinomycetemcomitans CDT is 
independent of classical inflammatory mediators. When purified H. ducreyi CDT was used as a model 
toxin to study RANKL induction in GF and PDL cells, it was alone able to induce RANKL, similarly 
to the wild-type A. actinomycetemcomitans strain. Alternatively, when it was added along with the 
CDT-mutant, it was able to rescue RANKL induction [45]. In another study employing T-cells, 
purified H. ducreyi CDT up-regulated RANKL gene expression and protein secretion, whereas OPG 
was not detected at all in this experimental system [46]. 
Collectively, CDT appears to induce RANKL, the key osteoclast-differentiating factor responsible 
for bone resorption, in several cell types of relevance to periodontal disease. Hence, this toxin of  
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A. actinomycetemcomitans may be a crucial virulence factor for the pathological bone resorption 
occurring during the process of localized aggressive periodontitis. 
Table 1. Summary of the literature: effects on cytolethal distending toxins (CDTs) on the 
production of host inflammatory mediators by various cell types. 
Species Target cell Effect CDT-dependence Reference 
A. actinom. GF IL-6 induction Partly [18] 
 GF/PDL cells RANKL induction Yes [45] 
 PBMCs 
IL-1β, IL-6, IL-8, IFN-γ 
induction 
Yes [11] 
 Macrophages NO, INF-γ inhibition Yes [17] 
 MNL cells NLRP3/NLRP6 regulation No [18] 
H. ducreyi GF/PDL cells RANKL induction Yes [45] 
 GF IL-6 induction Partly [18] 
 Various cell lines IL-6, IL-8, IL-24 induction Partly [28] 
 Dendritic cells 
TNF-α, IL-6, IL-8, IL-12 
inhibition 
Partly [29] 
 Jurkat T-cells RANKL induction Yes [46] 
C. jejuni Intestinal epithelium IL-8 induction Yes [30] 
 Colonic epithelium IL-8 induction Partly [33] 
H. hepaticus Hepatic tissue TNF-α, IFN-γ and IL-6 Yes [40] 
4. Conclusions 
Several Gram-negative pathogenic species produce a CDT. Apart from the well accepted effects  
on inhibition of cell cycle and induction of apoptosis in host cells, this toxin can also affect the 
transcription or production of some inflammatory mediators in diverse cell types, and may involve  
the TLR/NFκ-B pathway. The CDT-producing species with documented such capacities are  
A. actinomycetemcomitans, H. ducreyi, H. hepaticus and C. jejuni, while the affected inflammatory 
mediators are primarily RANKL, IL-6 and IL-8. This could have implications on the pathogenesis of 
the associated infections. In terms of future research, novel transcriptomic or proteomic approaches 
may be able to shed further light onto the global effects of CDTs, with regards to inflammatory 
responses, and other aspects of CDT-related toxicity. 
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